Infertility Drugs Market Size to Exceed USD 6.62 Bn by 2032

The Infertility Drugs Market, estimated at USD 4.18 Bn in 2025, is expected to exhibit a CAGR of 6.8% and reach USD 6.62 Bn by 2032.

The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.

Market Dynamics:

Global infertility drugs market growth is driven by increasing prevalence of infertility due to rising risk factors such as obesity, stress, sexually transmitted infections, polycystic ovary disease and other medical conditions. According to the CDC, around 12% of women aged 15-44 years in the U.S. have difficulty getting pregnant or carrying a pregnancy to term. Rising awareness about infertility treatment options and modern family planning methods, easy availability of generic infertility drugs, and government support in terms of fertility tourism can drive the market growth.

Rising prevalence of infertility due to lifestyle changes and medical conditions can drive the market growth

Infertility rates have been increasing significantly across the globe due to changing lifestyles and rising prevalence of medical conditions. More people are delaying parenthood to focus on their careers, resulting in infertility issues due to aging. The average age of first-time mothers has risen substantially in developed nations. Obesity, stress and other lifestyle diseases are also contributing to infertility among both men and women. All of these factors boosts demand for infertility treatment drugs and assisted reproductive technologies. Pharmaceutical companies have responded by developing newer and more effective drug therapies to boost fertility success rates. Continued investments in R&D can address the underlying causes of infertility more comprehensively.

Increasing awareness and social acceptance of infertility treatment globally can drive the market demand

There is growing societal awareness and reduced stigma associated with infertility issues and treatment worldwide. People are more open about discussing their fertility struggles and seeking medical help. Governments and non-profit organizations are educating the public about infertility as a medical condition that can often be treated successfully. Social media has also played a role in destigmatizing infertility and assisted conception. Growing social acceptance encourages more people to opt for IVF and other assisted reproduction methods. This boosts the uptake of infertility drugs that are prescribed as part of fertility treatment protocols. Drug companies are leveraging the positive shift in public perception to expand their patient reach.

High cost of treatment can hamper the market growth

 Global infertility drugs market growth can be hampered by prohibitively high cost of treatment, which limits access for many patients. A single IVF cycle can cost anywhere between US$ 12,000 to US$ 17,000 in the U.S. without insurance coverage. The lengthy and complex nature of fertility treatment involving multiple consultations, procedures, tests and drugs makes it very expensive. The high costs place treatment out of reach for low and middle-income individuals in developed as well as developing nations. Even with insurance, patients often have to bear a significant co-payment.

Stringent regulatory environment hampers the market growth

Global infertility drugs market is highly regulated to ensure quality, efficacy and safety of fertility medications. Regulators closely monitor new drug development, approval and use. While necessary to protect patient health, the complex regulatory compliance requirements lengthen drug development cycles and approval timelines. It also increases the costs and risks involved. The stringent nature of regulations deters small regional drug makers from entering this field. Moreover, regulations around embryo selection, storage and destruction vary greatly between countries posing additional compliance hurdles for global players. The regulatory complexities slightly dampen the enthusiasm of stakeholders to invest and innovate.

 Rising medical tourism opens new opportunities in developing markets

With significantly lower cost of fertility treatment in emerging Asian and Latin American countries compared to developed nations, medical tourism for infertility services is booming. Affordable yet high-quality IVF and associated drug therapies attract patients from Europe and North America. Countries like India, Thailand, Mexico offer 40-60% lower IVF package rates compared to the U.S. or U.K. This offers lucrative opportunities for local pharmaceutical companies to partner with IVF clinics and cater to the burgeoning medical tourist population. The thriving medical tourism industry encourages infrastructure building and industry investment, thus, driving the market growth.

Increase in single parenthood and same sex partnership create new market avenues

There has been huge demand for fertility treatment from single women and same sex couples who want to experience parenthood. Social progress towards acceptance and legalization of single parenthood and same sex marriage can drive the market growth. Pharma players are responding by developing tailored infertility treatment protocols involving sperm/egg donation and surrogacy specifically addressing the needs of these demographics. For instance, a new category of fertility preservation drugs help women delay motherhood and maintain future fertility. Same sex male partnership treatment also presents a promising avenue.

Link: https://www.coherentmarketinsights.com/market-insight/infertility-drugs-market-2665

Key Development

• In May 2024, Turkiye requested India for Gonadotropin drugs that are used in obstetrics and gynecology due to their huge demand for in-vitro fertilization (IVF) in the country.
• In February 2024, Lupin Limited introduced Ganirelix Acetate Injection, 250 mcg/0.5 mL, Single-Dose Prefilled Syringe in the U.S., following approval from the U.S. Food and Drug Administration (FDA). This product is a generic equivalent of Organon USA LLC's reference listed drug (RLD), Ganirelix Acetate Injection, and is aimed at treating infertility.
• In February 2023, Russia commenced domestic production of recombinant follicle-stimulating hormone and two other IVF medications. It also plans include using biotechnology to manufacture human chorionic gonadotropin hormone, aiming to address raw material shortages.
• In August 2022, the U.S. FDA approved Akorn Operating Company's cetrorelix acetate for injection, a generic version of Cetrotide. This approval allows the medication to prevent early luteinizing hormone surges in females undergoing controlled ovarian stimulation.

Key Players: Merck & Co., Inc., Ferring Pharmaceuticals, Pharma Mar, S.A., Novartis AG, Pfizer, Inc., Takeda Pharmaceutical Company Limited, Sanofi S.A., Teva Pharmaceutical Industries Ltd., LIVZON Pharmaceutical Group Inc., Fairfax EggBank, Inc., Genea Limited, Cook Medical Inc., Vitrolife, Thermo Fisher Scientific, Inc., CooperSurgical, Inc., Monash IVF Group, Finox Biotech (Finox AG)